Applying Synthetic Lethality for the Selective Targeting of Cancer

DNA-PKcs is required to maintain stability of Chk1 and Claspin for optimal replication stress response

(2014) Yu-Fen Lin et al.   NUCLEIC ACIDS RESEARCH

Modernizing the Nonhomologous End-Joining Repertoire: Alternative and Classical NHEJ Share the Stage

(2013) Ludovic Deriano et al.   Annual Review of Genetics

Identification of potential synthetic lethal genes to p53 using a computational biology approach

(2013) Xiaosheng Wang et al.   BMC Medical Genomics

Role of Expression Profiling in Carcinoma of Unknown Primary Remains Unknown

(2013) Leonard B. Saltz   JOURNAL OF CLINICAL ONCOLOGY

KRASMutation: Should We Test for It, and Does It Matter?

(2013) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy

(2013) Timothy J. Judson et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer

(2013) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy

(2013) Jan R. Dörr et al.   NATURE

Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers

(2013) M. Pourdehnad et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo

(2013) Sandra Morandell et al.   Cell Reports

Beyond DNA Repair: Additional Functions of PARP-1 in Cancer

(2013) Alice N. Weaver et al.   Frontiers in Oncology

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

(2012) J. Murai et al.   CANCER RESEARCH

Network Medicine Strikes a Blow against Breast Cancer

(2012) Janine T. Erler et al.   CELL

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

(2012) Madhu S. Kumar et al.   CELL

Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks

(2012) Michael J. Lee et al.   CELL

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies

(2012) Michael Steckel et al.   CELL RESEARCH

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma

(2012) D. Mahadevan et al.   CLINICAL CANCER RESEARCH

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

(2012) Elisabet Wahlberg et al.   NATURE BIOTECHNOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability

(2012) T. Luo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

(2011) Patrick Schöffski et al.   EUROPEAN JOURNAL OF CANCER

Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications

(2011) S. E. Polo et al.   GENES & DEVELOPMENT

A snapshot of chemoresistance to PARP inhibitors

(2011) Alberto Chiarugi   TRENDS IN PHARMACOLOGICAL SCIENCES

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

(2010) M. A. Vollebergh et al.   ANNALS OF ONCOLOGY

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

(2010) Sarah A. Martin et al.   CANCER CELL

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

(2010) N. Chan et al.   CANCER RESEARCH

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3

(2010) Amy Baldwin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

(2009) Claudia Scholl et al.   CELL

A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

(2009) Ji Luo et al.   CELL

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair geneMSH2

(2009) Sarah A. Martin et al.   EMBO Molecular Medicine

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

The DNA-damage response in human biology and disease

(2009) Stephen P. Jackson et al.   NATURE

A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation

(2009) Gyula Timinszky et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

(2009) S. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanism of Eukaryotic Homologous Recombination

(2008) Joseph San Filippo et al.   Annual Review of Biochemistry

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

(2008) N. Chan et al.   CANCER RESEARCH

Variation of Breast Cancer Risk Among BRCA1/2 Carriers

(2008) Colin B. Begg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair

(2008) Alan Ashworth   JOURNAL OF CLINICAL ONCOLOGY

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen

(2008) Benjamin L. Ebert et al.   NATURE